GlassScriptPhysician profile
Joo H Schmidt
NPI 1972158541
$1,103.19
in general payments reported to CMS, 2019-2025
16 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.02 · 2022: $47.31 · 2023: $529 · 2024: $119 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.88 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $205.32 | 2022-2025 | Jakafi, Niktimvo |
| Astellas Pharma US INC | $177.97 | 2023-2025 | Xospata, Cresemba |
| Sobi, INC | $145.05 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $101.60 | 2025 | |
| Pharmaessentia USA Corporation | $85.34 | 2023-2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $80.91 | 2022-2023 | Calquence |
| Novartis Pharmaceuticals Corporation | $61.96 | 2023-2024 | |
| Lilly USA, LLC | $51.86 | 2023 | Jaypirca |
| Celgene Corporation | $33.85 | 2025 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $30.95 | 2023 | Tavalisse, Rezlidhia |
| Blueprint Medicines Corporation | $27.84 | 2025 | Ayvakit |
| Cti Biopharma Corp. | $27.00 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $26.88 | 2023 | Ojjaara |
| Azurity Pharmaceuticals, INC. | $17.14 | 2025 | Danziten |
| Karyopharm Therapeutics INC. | $15.02 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $14.50 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joo Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.